ArticleRNA (New York, N.Y.)2005
A novel RNA pentaloop fold involved in targeting ADAR2.
Article in RNA (New York, N.Y.), 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 34 citations in OpenAlex.
- RNA editing in disease: mechanisms and therapeutic potential.RNA (New York, N.Y.) · 2025Review
- Identification and characterization of RNA pentaloop sequence families.NAR genomics and bioinformatics · 2023Article
- Article
- The important conformational plasticity of DsrA sRNA for adapting multiple target regulation.Nucleic acids research · 2017Article
- Understanding RNA modifications: the promises and technological bottlenecks of the 'epitranscriptome'.Open biology · 2017Review
- Nuclear Magnetic Resonance-Assisted Prediction of Secondary Structure for RNA: Incorporation of Direction-Dependent Chemical Shift Constraints.Biochemistry · 2015Article
- mRNA expression, splicing and editing in the embryonic and adult mouse cerebral cortex.Nature neuroscience · 2013Article
- Article
- Activity-regulated RNA editing in select neuronal subfields in hippocampus.Nucleic acids research · 2013Article
- ADAR proteins: double-stranded RNA and Z-DNA binding domains.Current topics in microbiology and immunology · 2012Review
- A structural determinant required for RNA editing.Nucleic acids research · 2011Article
- Article
- Regulation of PKR by HCV IRES RNA: importance of domain II and NS5A.Journal of molecular biology · 2010Article
- Bacteriophage P22 antitermination boxB sequence requirements are complex and overlap with those of lambda.Journal of bacteriology · 2008Article
- RNA aptamers binding the double-stranded RNA-binding domain.RNA (New York, N.Y.) · 2006Article
- Structure of the Tetrahymena thermophila telomerase RNA helix II template boundary element.Nucleic acids research · 2006Article
- Biochemical and genomic analysis of substrate recognition by the double-stranded RNA binding domain of yeast RNase III.RNA (New York, N.Y.) · 2005Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Adenosine deaminases that act on RNA (ADARs) catalyze the site-specific conversion of adenosine to inosine in primary mRNA transcripts, thereby affecting coding potential of mature mRNAs. Structural determinants that define the adenosine moieties for specific ADARs-mediated deaminations are currently unknown. We report the solution structure of the central region of the human R/G stem-loop pre-mRNA, a natural ADAR2 substrate encoding the subunit B of the glutamate receptor (R/G site). The structure reveals that the GCU(A/C)A pentaloop that is conserved in mammals and birds adopts a novel fold. The fold is stabilized by a complex interplay of hydrogen bonds and stacking interactions. We propose that this new pentaloop structure is an important determinant of the R/G site recognition by ADAR2.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.